文献速递心境障碍老年精神

经皮雌二醇联合微粒化黄体酮预防绝经过渡期抑郁症状的随机临床试验

Efficacy of Transdermal Estradiol and Micronized Progesterone in the Prevention of Depressive Symptoms in the Menopause Transition: A Randomized Clinical Trial.
PubMed 文献 · JAMA Psychiatry · 2018-01-01

该双盲安慰剂对照随机试验纳入172名45至60岁心境正常的围绝经期和绝经早期女性,评估经皮雌二醇(0.1 mg/d)联合间断口服微粒化黄体酮(200 mg/d,每3个月用12天)预防临床显著抑郁症状的疗效。结果显示,安慰剂组CES-D≥16的发生率显著高于治疗组(32.3% vs 17.3%;OR 2.5;95%CI 1.1-5.7;疗效在绝经早期过渡阶段和经历较多应激生活事件者中更明显。

要点

  • 经皮雌二醇联合间断微粒化黄体酮可降低围绝经期及绝经早期女性临床显著抑郁症状的发生风险。
  • 疗效在绝经早期过渡阶段女性中显著,在绝经晚期过渡和绝经后女性中未观察到显著获益。
  • 近6个月应激生活事件越多,治疗对平均CES-D评分的改善作用越明显。

核心结论

  • 12个月经皮雌二醇联合间断口服微粒化黄体酮治疗在初始心境正常的围绝经期和绝经早期女性中,比安慰剂更有效预防临床显著抑郁症状的发生。

研究设计与样本

  • 研究为双盲、安慰剂对照随机临床试验,在北卡罗来纳大学教堂山分校于2010年10月至2016年2月开展。
  • 共纳入172名来自社区的45至60岁心境正常的围绝经期和绝经早期女性。
  • 干预为经皮雌二醇0.1 mg/d或安慰剂贴剂持续12个月;活性治疗组每3个月口服微粒化黄体酮200 mg/d连续12天,安慰剂组给予相同安慰剂片。
  • 主要结局为基线及随机后第1、2、4、6、8、10、12个月评估的流行病学研究中心抑郁量表(CES-D)评分,以及临床显著抑郁症状(CES-D评分≥16)的发生率。

主要发现

  • 172名参与者中130名为白人(76%),70名为非裔美国人(19%),平均家庭收入为50 000至79 999美元,平均年龄51岁,共43人出现临床显著抑郁症状。

关键数值与推荐

  • 临床显著抑郁症状定义为CES-D评分至少16分。
  • TE+IMP方案为经皮雌二醇0.1 mg/d持续12个月,联合口服微粒化黄体酮200 mg/d每3个月连续12天。

临床怎么用

  • 对于心境正常的绝经过渡期女性,尤其是处于绝经早期过渡阶段且近期应激生活事件较多者,可考虑经皮雌二醇联合间断微粒化黄体酮以预防临床显著抑郁症状。
  • 治疗决策需结合生殖阶段和应激生活事件评估,绝经晚期过渡及绝经后女性中未观察到显著预防获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: The menopause transition and early postmenopausal period are associated with a 2- to 4-fold increased risk for clinically significant depressive symptoms. Although a few studies suggest that hormone therapy can effectively manage existing depression during this time, to our knowledge, there have been no studies testing whether hormone therapy can prevent the onset of perimenopausal and early postmenopausal depressive symptoms. OBJECTIVE: To examine the efficacy of transdermal estradiol plus intermittent micronized progesterone (TE+IMP) in preventing depressive symptom onset among initially euthymic perimenopausal and early postmenopausal women. A secondary aim was to identify baseline characteristics predicting TE+IMP's beneficial mood effects. DESIGN, SETTING, AND PARTICIPANTS: Double-blind, placebo-controlled randomized trial at the University of North Carolina at Chapel Hill from October 2010 to February 2016. Participants included euthymic perimenopausal and early postmenopausal women from the community, aged 45 to 60 years. INTERVENTIONS: Transdermal estradiol (0.1 mg/d) or transdermal placebo for 12 months. Oral micronized progesterone (200 mg/d for 12 days) was also given every 3 months to women receiving active TE, and identical placebo pills were given to women receiving placebo. MAIN OUTCOME MEASURES: Scores on the Center for Epidemiological Studies-Depression Scale (CES-D), assessed at baseline and months 1, 2, 4, 6, 8, 10, and 12 after randomization, and the incidence of clinically significant depressive symptoms, defined as a CES-D score of at least 16. RESULTS: Of 172 participants, 130 were white (76%), and 70 were African American (19%), with a mean household income of $50 000 to $79 999. The mean age was 51 years, and 43 developed clinically significant depressive symptoms. Women assigned to placebo were more likely than those assigned to TE+IMP to score at least 16 on the CES-D at least once during the intervention phase (32.3% vs 17.3%; odds ratio [OR], 2.5; 95% CI, 1.1-5.7; P = .03) and had a higher mean CES-D score across the intervention period (P = .03). Baseline reproductive stage moderated the effect of treatment (β, -1.97; SEM, 0.80; P for the interaction = .03) such that mood benefits of TE+IMP vs placebo were evident among women in the early menopause transition (β, -4.2; SEM, 1.2; P < .001) but not the late menopause transition (β, -0.9; SEM, 0.3; P = .23) or among postmenopausal women (β, -0.3; SEM, 1.1; P = .92). Stressful life events in the 6 months preceding enrollment also moderated the effect of treatment on mean CES-D score such that the mood benefits of TE+IMP increased with a greater number of events (β, 1.22; SEM, 0.40; P = .003). Baseline estradiol levels, baseline vasomotor symptoms, history of depression, and history of abuse did not moderate treatment effects. CONCLUSIONS: Twelve months of TE+IMP were more effective than placebo in preventing the development of clinically significant depressive symptoms among initially euthymic perimenopausal and early postmenopausal women. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT01308814.

来源:JAMA Psychiatry,查看原文。版权归原作者所有。

引用

  1. Gordon JL, Rubinow DR, Eisenlohr-Moul TA, et al. Efficacy of Transdermal Estradiol and Micronized Progesterone in the Prevention of Depressive Symptoms in the Menopause Transition: A Randomized Clinical Trial. JAMA Psychiatry. 2018. PMID: 29322164. doi:10.1001/jamapsychiatry.2017.3998

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。